1.—(1) Section 88 of the National Health Service Act 2006 M1 (GMS contracts: prescription of drugs, etc) is amended as follows.
(2) In subsection (3), for “Community marketing authorization or United Kingdom” substitute “ UK ”.
(3) For subsection (4) substitute—
“(4) “UK marketing authorisation” has the meaning given by regulation 8(1) of the Human Medicines Regulations 2012 (S.I. 2012/1916) M2.”.
Commencement Information
I1Sch. 8 para. 1 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
Marginal Citations
2. In section 3(2)(b) and (4)(a), (b) and (c) of the Access to Medical Treatments (Innovation) Act 2016 M3 (provision supplementary to section 2: database of innovative treatments) insert “ UK ” before “marketing authorisation”.
Commencement Information
I2Sch. 8 para. 2 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
Marginal Citations